dranupdhir@hotmail.com 
Before reaching for a brightening product, it helps to understand what's actually causing the dark patch. Sun damage, post-inflammatory hyperpigmentation from old acne, melasma, and age spots all involve melanin, but they involve it differently. The treatment that works for one doesn't necessarily work for another. Knowing where in the melanin production process the problem sits is what allows treatment to be matched correctly.
Melanin is produced by melanocytes, specialised cells sitting in the basal layer of the epidermis. Its primary biological function is photo protection. When skin is exposed to UV radiation, melanocytes increase production and distribute melanin to surrounding keratinocytes, which carry it toward the skin surface. Hyperpigmentation happens when that activity becomes localised or uneven, driven by UV exposure, inflammation, or hormonal changes.
The enzyme that drives melanin synthesis is tyrosinase. It converts tyrosine, an amino acid, into DOPA and then into dopaquinone, which eventually becomes melanin. Most clinically proven brightening ingredients work by interfering with tyrosinase somewhere in that chain, or by blocking the steps that follow.
Hydroquinone has been the standard prescription brightening agent for decades. It inhibits tyrosinase directly and also disrupts the metabolic processes inside the melanocyte. At 4% concentration, used under medical supervision, it produces measurable results for melasma, post-inflammatory hyperpigmentation, and solar lentigines. Long-term unsupervised use carries a risk of ochronosis, a rare but permanent darkening of the skin, which is why it's used in supervised, time-limited courses.
Vitamin C (ascorbic acid) works by reducing dopaquinone back to DOPA before it converts to melanin, and by quenching the free radicals that trigger melanin production. At 10 to 20% concentration in a stable formulation, it's one of the more effective non-prescription brightening ingredients. Vitamin C oxidises on exposure to light and air, so formulation quality and packaging affect how much active ingredient actually reaches the skin.
Niacinamide doesn't inhibit tyrosinase but works downstream, blocking the transfer of melanosomes from melanocytes to keratinocytes. Studies at 5% concentration show visible reduction in hyperpigmentation over 8 to 12 weeks. It's well tolerated across skin types, which makes it practical for consistent daily use.
Tranexamic acid, originally used clinically to reduce surgical bleeding, has found a well-evidenced role in treating melasma. Both topical and oral forms have shown results. It works by blocking the keratinocyte-melanocyte signalling that drives melanin production in response to UV exposure and inflammation. A PubMed systematic review found oral tranexamic acid to be one of the safer and more promising systemic options for hyperpigmentation treatment.
Kojic acid, derived from fungal fermentation, inhibits tyrosinase and has a reasonable evidence base in cosmetic formulations. Azelaic acid works similarly and adds anti-inflammatory properties, making it particularly relevant for post-acne pigmentation where inflammation is still a factor.
Chemical peels using glycolic, lactic, or salicylic acid accelerate cell turnover, moving pigmented cells toward the surface and shedding them faster than normal. They suit surface-level hyperpigmentation and general skin texture improvement. Depth of peel determines both how much improvement is achievable and how much downtime is involved.
Laser treatments target melanin directly using wavelengths selectively absorbed by pigment. Q-switched Nd: YAG and fractional lasers are used for solar damage, hyperpigmentation, and melasma. Melasma tends to recur without sustained sun protection even after successful laser treatment. In darker skin tones, parameter selection requires particular experience, because post-inflammatory hyperpigmentation from laser exposure is a real complication when the protocol isn't matched to the patient's skin type.
IV glutathione for systemic skin whitening is widely marketed across South and Southeast Asia but is not supported by rigorous evidence for sustained efficacy or systemic safety. Dermatology guidelines do not recommend it. Oral glutathione shows preliminary clinical promise and a better safety profile. Mercury-containing products, sold in several markets, cause kidney damage with sustained use. Any product without full ingredient disclosure should be avoided.
Dr. Anup Dhir has practised plastic and aesthetic surgery for over four decades. At Image Medical Center, Nehru Place, New Delhi, skin brightening concerns are assessed individually, because the right approach depends on what's driving the pigmentation, the patient's skin type, and the outcome they're trying to reach.
Dr. Anup Dhir was the first plastic surgeon in India accepted as an international active member of the American Society of Aesthetic Plastic Surgery. Patients with melasma, post-acne marks, uneven skin tone, or solar pigmentation benefit from a clinical assessment before any protocol is decided.
Leave a request to connect to Dr. Anup Dhir for an Appointment.